FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations By Ogkologos - July 25, 2025 343 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Oncomine Dx Express Test as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Responds to Public Consultation on EU4Health Work Programme for 2027... June 15, 2026 “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... November 25, 2020 Καρκίνος Δέρματος January 20, 2019 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Load more HOT NEWS 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... Navigating Your Care During Long-Term Cancer Survivorship Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous...
